Drugs / PEG-IFN alfa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00610389 Background | Feb 2008 → Apr 2010 | hepatocellular carcinoma, melanoma, renal cell carcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IFN alfa | “systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity” NCT00610389 ↗ |